Alpha Tau Medical

Update in progress

DRTS (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Alpha Tau Medical Ltd is a clinical-stage oncology company developing diffusing alpha-emitters radiation therapy (Alpha DaRT) to treat solid cancers. The Alpha-DaRT program is in clinical trials for skin, oral, pancreatic, prostate, lung, liver, and breast cancers, with preclinical work in mouse and human-derived tumor models. The company is headquartered in Jerusalem, Israel.

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationIsrael
CEOMr. Uzi Sofer
Employees121
Websitewww.alphatau.com

Identifiers

ISINIL0011839383
FIGIBBG00H5XSKB7
CIK0001871321